HER2-Negative Breast Cancer Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

The battle against cancer continues, with HER2 negative breast cancer being a prominent focus in the fight against this formidable disease. A recent report sheds light on the state of the global HER2 negative breast cancer treatment market, offering critical insights into trends, therapies, and key players in this critical healthcare sector.

Understanding HER2 Negative Breast Cancer Breast cancer is a complex group of diseases characterized by the uncontrolled division of cells, forming tumors. The type of breast cancer is often named after the part of the body where the tumor originates. In the case of HER2 negative breast cancer, the tumor lacks an overexpression of the HER2 or ERBB2 gene, making it a distinct subtype.

HER2 Negative Breast Cancer Overview According to data published by ASCO (American Society of Clinical Oncology), ductal carcinomas account for approximately 75% of all breast cancer cases. These cancers originate either in the lobules or ducts of the breast. Lobular carcinoma starts in the lobules, while ductal carcinoma begins in the ducts connected to the lobules. Invasive ductal or invasive carcinoma occurs when the cancer spreads beyond these structures.

Critical Role of HER2 Testing To determine the appropriate treatment for HER2 negative breast cancer, receptor testing plays a vital role. Three common tests are employed to assess HER2 levels chromogenic in situ hybridization (CISH), immunohistochemistry (IHC), and fluorescent in situ hybridization (FISH). Depending on the levels of HER2 in these tests, breast cancer is classified as HER2 positive or HER2 negative. HER2 is a receptor that plays a crucial role in breast cancer growth and division.

Tailored Treatment Approaches Treatment for HER2 negative breast cancer varies based on receptor status. Hormonal therapy is a key approach for HER2 negative breast cancer that is estrogen receptor (ER) positive, aiming to reduce estrogen levels or block its effects. However, for the challenging subtype of Triple Negative Breast Cancer (TNBC), where cancer cells lack estrogen, progesterone, and HER2 receptors, hormonal therapy is not effective.

Market Dynamics The global HER2 negative breast cancer treatment market is driven by the increasing incidence and prevalence of breast cancer worldwide. The pipeline of drugs for HER2 negative breast cancer and breast cancer in general also fuels market growth. However, challenges include treatment side effects like chemotherapy, the risk of tumor recurrence in many cases, and the stress and cost of multiple treatments.

Market Segmentation The HER2 negative breast cancer treatment market is segmented by treatment type into chemotherapy, radiation, surgery, and hormonal therapy. Hormonal therapy includes various approaches like Selective estrogen-receptor response modulators (SERMs), Estrogen-receptor downregulators (ERDs), Aromatase inhibitors, and Luteinizing hormone-releasing hormone agents (LHRHs).

Global Presence Geographically, the global HER2 negative breast cancer treatment market is segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. Key players in this market include Array BioPharma, AstraZeneca plc., CELGENE CORPORATION, Eli Lilly and Company, Novartis AG, AbbVie Inc, Merck & Co., Inc, Pfizer Inc, and more.


This product will be delivered within 1-3 business days.